Background: The present work aims to formulate nanostructured lipid carriers (NLCs) exhibiting high skin deposition and high inherent antioxidant potential to repurpose the use of melatonin hormone and some antioxidant oils in the treatment of androgenic alopecia (AGA). Research design and methods: NLCs were characterized for their size, charge, drug entrapment, anti-oxidant potential, physical stability, in vitro release, surface morphology, and ex-vivo skin deposition. Their merits were clinically tested on patients suffering from AGA by calculating the degree of improvement, conduction of hair pull test, histometric assessment, and dermoscopic evaluation. Results: Results revealed that melatonin NLCs showed nanometer size, negatively charged surface, high entrapment efficiency, and high anti-oxidant potential, in addition to sustained release for 6 h. Furthermore, NLCs displayed good storage stability and they were able to increase the skin deposition of melatonin 4.5-folds in stratum corneum, 7-folds in epidermis, and 6.8-folds in the dermis compared to melatonin solution. Melatonin NLCs displayed more clinically desirable results compared to the melatonin solution in AGA patients, manifested by increased hair density and thickness and decreased hair loss. Conclusions: The aforementioned system was shown to be a very promising treatment modality for AGA, which is worthy of futuristic experimentation.
1 September 2018 in European Journal of Pharmaceutical Sciences
Background: Nanotechnology has provided substantial benefits in drug delivery, especially in the treatment of dermatological diseases. Psoriasis is a chronic inflammatory skin disease in which topical delivery of antipsoriatic agents is considered the first line treatment. Objective: To investigate whether the encapsulation of the synthetic retinoid tazarotene in a nanocarrier based on jojoba oil would decrease its irritation potential and clinically improve its therapeutic outcome in psoriatic patients. Method: A microemulsion system based on jojoba wax and labrasol/plurol isostearique was prepared and characterized. Results: The selected formula displayed spherical morphology, particle size of 15.49±2.41 nm, polydispersity index of 0.20 ±0.08, negative charge and low viscosity. The microemulsion provided two folds increase in skin deposition of tazarotene, correlating with higher reduction in psoriatic patients PASI scores after treatment (68% reduction in PASI scores versus 8.96% reduction with the marketed gel). No irritation was encountered in patients using microemulsion, with redness and inflammation reported with the marketed gel-treated patients. Conclusion: Jojoba oil microemulsion proved to be advantageous in reducing the irritancy of tazarotene, enhancing its skin deposition and achieving better therapeutic outcome in psoriatic patients.
Aim: To study whether the formulation of an antifungal drug in nanovesicular form containing skin penetration enhancer would clinically modulate its therapeutic effectiveness. Materials & methods: Nanovesicles containing different skin penetration enhancers ‘PEVs’ were prepared and loaded with sertaconazole. Penetration-enhancer vesicles were characterized for entrapment efficiency, particle size, zeta potential, elasticity, viscosity, morphology and ex vivo skin deposition. Selected formulae were preliminary tested for clinical efficacy on patients suffering from tinea corporis and tinea versicolor. Results & conclusion: The nanosize of the vesicles, their content of penetration enhancer and their deformable nature are three cornerstones positively influencing the therapeutic outcome of topical antifungal therapy, and hence, can be considered a promising treatment modality for skin fungal diseases.